Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. The company provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.
IPO Year:
Exchange: NYSE
Website: owens-minor.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $24.00 → $19.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $24.00 | Market Perform | Leerink Partners |
| 1/3/2024 | $21.00 | Equal Weight | Barclays |
| 10/13/2022 | $52.00 → $18.00 | Buy → Neutral | Citigroup |
| 10/12/2022 | $43.00 → $17.00 | Buy → Underperform | BofA Securities |
| 10/12/2022 | $62.00 → $22.00 | Outperform → Neutral | Robert W. Baird |
| 4/26/2022 | $55.00 | Buy | Citigroup |
| 4/1/2022 | $43.00 | Neutral | Credit Suisse |
| 3/30/2022 | $46.00 | Underweight | JP Morgan |
| 2/28/2022 | $42.00 → $43.00 | Neutral | Credit Suisse |
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
DEFA14A - OWENS & MINOR INC/VA/ (0000075252) (Filer)
DEF 14A - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
10-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b
Transformative investments in technology, automation and analytics capabilities will help improve supply chain visibility and resiliency for Products & Healthcare Services customers and lay the foundation for future innovations Owens & Minor, Inc. (NYSE:OMI) today announced important milestones in advancing the medical distribution capabilities of its Products & Healthcare Services (P&HS) business segment, which provides essential products and services to thousands of healthcare customers. These milestones are the result of recent company investments in new technology, automation and analytics capabilities geared specifically toward driving greater efficiencies for the P&HS segment and imp
Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced today the upsize and pricing of its private offering (the "Offering") of $1 billion aggregate principal amount of its 10.000% senior secured notes due 2030 (the "Notes"). The Offering is expected to close on April 4, 2025, subject to customary closing conditions. The Notes will bear interest at the rate of 10.000% per year. The Notes will mature on April 15, 2030 (subject to certain earlier maturity triggers). The Notes were offered at a price of 100% of their principal amount. Unless the previously announced acquisition (the "Acquisition") of Rotech Healthcare Holdings Inc. ("Rotech") is consummated substantially concurrently with t
Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced today that it has launched a private offering (the "Offering") of $600 million aggregate principal amount of senior secured notes due 2030 (the "Notes"), subject to customary and market conditions. Unless the previously announced acquisition (the "Acquisition") of Rotech Healthcare Holdings Inc. ("Rotech") is consummated concurrently with or promptly following the closing of the Offering, the Company will deposit the gross proceeds from the Offering into a segregated escrow account until the date that certain escrow release conditions, including the consummation of the Acquisition, have been satisfied. The consummation of the Acquisi
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod
Now available as a free service exclusively to Byram Healthcare customers, ByramConnect powered by the Welldoc App combines digital health coaching, self-tracking, clinically relevant insights and education to support members with diabetes and associated chronic health conditions throughout their health journey. Byram Healthcare, a leader in home-based care and part of the Owens & Minor (NYSE:OMI) family, recently launched ByramConnectTM, a personalized digital health program powered by the Welldoc App®. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or
Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 Owens & Minor, Inc. (NYSE:OMI) (the "Company") today announced selected preliminary financial results for the fourth quarter and year ended December 31, 2024 in advance of its upcoming earnings announcement and conference call. The release of the preliminary results relates to the Company's commencement of financing activity related to its previously announced agreement to acquire Rotech Healthcare Holdings, Inc ("Rotech"). "We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to acquire Rotech which we continu
Owens & Minor, Inc. (NYSE:OMI), announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2024 Global Healthcare Conference On Wednesday, December 4, 2024, Owens & Minor is scheduled to participate in a fireside chat at 8:45 a.m. ET and host individual investor meetings at the conference in Miami, Florida. Bank of America Home Care Conference On Monday, December 9, 2024, Owens & Minor is scheduled to participate in a fireside chat at 12:00 p.m. ET and host individual investor meetings at the virtual conference. About Owens & Minor Owens & Minor, Inc. ((OMI) is a Fortune 500 global healthcare solutions company providing
Top-Line Growth Driven by Continued Solid Demand in Patient Direct and Medical Distribution Total Debt Reduction of Nearly $200 Million in the Third Quarter Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2024. Key Highlights: Consolidated revenue of $2.7 billion in the third quarter, representing year-over-year growth of 5% GAAP Net loss of $(13) million or $(0.17) per share, and adjusted earnings per share of $0.42 in the third quarter Adjusted EBITDA of $142 million in the third quarter, representing year-over-year growth of 5% $198 million in total debt reduction in the third quarter "Our third quarter results demons
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously
Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00
Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00
Citigroup downgraded Owens & Minor from Buy to Neutral and set a new price target of $18.00 from $52.00 previously
BofA Securities downgraded Owens & Minor from Buy to Underperform and set a new price target of $17.00 from $43.00 previously
Robert W. Baird downgraded Owens & Minor from Outperform to Neutral and set a new price target of $22.00 from $62.00 previously
Citigroup resumed coverage of Owens & Minor with a rating of Buy and set a new price target of $55.00
Credit Suisse resumed coverage of Owens & Minor with a rating of Neutral and set a new price target of $43.00
JP Morgan resumed coverage of Owens & Minor with a rating of Underweight and set a new price target of $46.00
Credit Suisse reiterated coverage of Owens & Minor with a rating of Neutral and set a new price target of $43.00 from $42.00 previously
Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod
Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 Owens & Minor, Inc. (NYSE:OMI) (the "Company") today announced selected preliminary financial results for the fourth quarter and year ended December 31, 2024 in advance of its upcoming earnings announcement and conference call. The release of the preliminary results relates to the Company's commencement of financing activity related to its previously announced agreement to acquire Rotech Healthcare Holdings, Inc ("Rotech"). "We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to acquire Rotech which we continu
Top-Line Growth Driven by Continued Solid Demand in Patient Direct and Medical Distribution Total Debt Reduction of Nearly $200 Million in the Third Quarter Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2024. Key Highlights: Consolidated revenue of $2.7 billion in the third quarter, representing year-over-year growth of 5% GAAP Net loss of $(13) million or $(0.17) per share, and adjusted earnings per share of $0.42 in the third quarter Adjusted EBITDA of $142 million in the third quarter, representing year-over-year growth of 5% $198 million in total debt reduction in the third quarter "Our third quarter results demons
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the third quarter of 2024 on Monday, November 4, 2024, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. ET on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can
Top Line Expansion Driven by Solid Growth in Both Segments Second Quarter Operating Cash Flow of $116 Million Drove $71 million in Debt Reduction Expanding Patient Direct Segment with Agreement to Acquire Rotech Healthcare Holdings Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the second quarter ended June 30, 2024. Key Highlights: Consolidated revenue of $2.7 billion in the second quarter, representing year-over-year growth of 4% Net loss of $(32) million or $(0.42) per share in the second quarter Adjusted EBITDA of $127 million in the second quarter, representing year-over-year growth of 12% Doubled second quarter year over year Adjusted earnings
Plans to Release Full Results on Friday, August 2 Before the NYSE Open Owens & Minor, Inc. (NYSE:OMI) today announced selected preliminary financial results for the quarter ended June 30, 2024 as noted in the table below. The Company also reaffirmed its outlook for the full year 2024 as noted below in advance of its second quarter 2024 earnings announcement and conference call. Selected Preliminary Financial Results for the Quarter Ended June 30, 2024 (1) ($ in millions, except per share data) 2Q24 Revenue $2,651 - $2,671 Operating income, GAAP $16 - $20 Adj. Operating Income, Non-GAAP
Strategy Articulated at Investor Day is Advanced by Strengthening Our Patient Direct Segment's Position as a Premier Growth Platform in Home-Based Care Combined Capabilities Support Improved Service to Patients, Providers, and Payors Adjusted EPS Neutral in First Full Year and Approximately $0.15 Accretion in Second Year Company Reports Preliminary Second Quarter Results and Reaffirms 2024 Full Year Guidance in Separate Press Release Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI), today announced that it has entered into a definitive agreement to acquire Rotech Healthcare Holdings, Inc. ("Rotech"), a privately held home based care business headquartered in Orlando, Florida, for $1
Gross Margin Expansion of 79 Basis Points Adjusted EPS Growth of Nearly Four Times with GAAP EPS Loss of $(0.29) and Adjusted EPS of $0.19 Investments Outlined at 2023 Investor Day for Long-Term Growth are Ahead of Plan Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2024. Key Highlights: Consolidated revenue of $2.6 billion in the first quarter, representing year-over-year growth of 4% GAAP operating margin was flat while adjusted operating margin expanded by 31 basis points versus prior year Net loss per share of $(0.29) and adjusted earnings per share of $0.19 in the first quarter "Our solid performance in the firs
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)